Grifols revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Learn more on GRFS stock here.

These samples are part of Grifols’ extensive plasma repository, which contains more than 100 million specimens collected over nearly 15 years. Their medical value is in their link to real-world ...

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other ...

GRIFOLS transfer bags are used for sterile preservation and administration of blood components. Blood components can be obtained, stored and preserved without contact with the environment ensuring ...

Grifols SA engages in the production of plasma ... The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked ...

Grifols is anticipating a period of strong growth ... As the news that NHS England is to be dismantled sinks in, the British Medical Association (BMA) and other bodies have weighed in on the ...

February 27, 2025 Grifols prevé aumentar ingresos y flujo de caja libre, y sus acciones se disparan La farmacéutica española Grifols dijo el jueves que espera que sus ingresos, utilidades ...

Muddy Waters CEO Carson Block picked Grifols (GRFS) as a short for the Robin Hood Foundation’s stock picking contest. However, said in an interview that Muddy Waters is “not actually short it ...

Grifols (GRFS) hosted it 2025 Capital Markets Day on February 27 in London, where the company announced it would double revenue to EUR 14 billion over the next decade as part of an ambitious ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the ...